BR112016008996A2 - Ligante peptídico específico para calicreína plasmática e composição farmacêutica - Google Patents

Ligante peptídico específico para calicreína plasmática e composição farmacêutica

Info

Publication number
BR112016008996A2
BR112016008996A2 BR112016008996A BR112016008996A BR112016008996A2 BR 112016008996 A2 BR112016008996 A2 BR 112016008996A2 BR 112016008996 A BR112016008996 A BR 112016008996A BR 112016008996 A BR112016008996 A BR 112016008996A BR 112016008996 A2 BR112016008996 A2 BR 112016008996A2
Authority
BR
Brazil
Prior art keywords
kallicrein
plasma
pharmaceutical composition
specific peptide
peptide binder
Prior art date
Application number
BR112016008996A
Other languages
English (en)
Other versions
BR112016008996B1 (pt
Inventor
Teufel Daniel
Stace Catherine
Walker Edward
Original Assignee
Bicycle Therapeutics Ltd
Bicyclerd Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB201318941A external-priority patent/GB201318941D0/en
Priority claimed from GB201410265A external-priority patent/GB201410265D0/en
Application filed by Bicycle Therapeutics Ltd, Bicyclerd Ltd filed Critical Bicycle Therapeutics Ltd
Publication of BR112016008996A2 publication Critical patent/BR112016008996A2/pt
Publication of BR112016008996B1 publication Critical patent/BR112016008996B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

POLIPEPTÍDIOS. A presente invenção refere-se a polipeptídios que são covalentemente ligados a cadafalsos moleculares de modo que duas ou mais alças peptídicas ficam subtendidas entre pontos de ligação ao cadafalso. Em particular, a invenção descreve peptídios que são específicos para a protease calicreína plasmática humana e de rato e são modificados em uma ou duas alças peptídicas para aumentar a potência e/ou a resistência à protease.
BR112016008996-0A 2013-10-28 2014-10-28 Ligante peptídico específico para calicreína plasmática e composição farmacêutica BR112016008996B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1318941.0 2013-10-28
GB201318941A GB201318941D0 (en) 2013-10-28 2013-10-28 Novel polypeptides
GB201410265A GB201410265D0 (en) 2014-06-10 2014-06-10 Novel polypeptides
GB1410265.1 2014-06-10
PCT/GB2014/053199 WO2015063465A2 (en) 2013-10-28 2014-10-28 Novel polypeptides

Publications (2)

Publication Number Publication Date
BR112016008996A2 true BR112016008996A2 (pt) 2017-10-03
BR112016008996B1 BR112016008996B1 (pt) 2023-01-24

Family

ID=51871092

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016008996-0A BR112016008996B1 (pt) 2013-10-28 2014-10-28 Ligante peptídico específico para calicreína plasmática e composição farmacêutica

Country Status (12)

Country Link
US (2) US10294274B2 (pt)
EP (1) EP3062823B1 (pt)
JP (3) JP2017502921A (pt)
CN (1) CN105683211B (pt)
AU (2) AU2014343503B2 (pt)
BR (1) BR112016008996B1 (pt)
CA (1) CA2927554C (pt)
ES (1) ES2715379T3 (pt)
NZ (1) NZ719510A (pt)
RU (1) RU2674604C2 (pt)
SG (1) SG11201602889TA (pt)
WO (1) WO2015063465A2 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3299377T (lt) 2011-10-07 2021-03-25 Bicyclerd Limited Struktūrizuoto polipeptido specifiškumo moduliavimas
GB201306623D0 (en) 2013-04-11 2013-05-29 Bicycle Therapeutics Ltd Modulation of structured polypeptide specificity
BR112016008996B1 (pt) * 2013-10-28 2023-01-24 Bicyclerd Limited Ligante peptídico específico para calicreína plasmática e composição farmacêutica
GB201607827D0 (en) 2016-05-04 2016-06-15 Bicycle Therapeutics Ltd Bicyclic peptide-toxin conjugates specific for MT1-MMP
US11730819B2 (en) 2016-12-23 2023-08-22 Bicycletx Limited Peptide derivatives having novel linkage structures
JP7301757B2 (ja) 2017-06-26 2023-07-03 バイスクルアールディー・リミテッド 検出可能部分を持つ二環式ペプチドリガンドおよびその使用
CN107557476A (zh) * 2017-08-25 2018-01-09 华侨大学 一种分析苏云金杆菌制剂对靶虫活性低下原因的方法
EP3675889A4 (en) * 2017-08-31 2021-05-12 Singapore Health Services PTE Ltd ANGIO -3 FOR THE TREATMENT OF ANGIOGENIC RETINAL DISEASES
TWI825046B (zh) 2017-12-19 2023-12-11 英商拜西可泰克斯有限公司 Epha2特用之雙環胜肽配位基
GB201721265D0 (en) 2017-12-19 2018-01-31 Bicyclerd Ltd Bicyclic peptide ligands specific for EphA2
GB201810316D0 (en) 2018-06-22 2018-08-08 Bicyclerd Ltd Peptide ligands for binding to EphA2
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
GB201810327D0 (en) * 2018-06-22 2018-08-08 Bicycletx Ltd Peptide ligands for binding to IL-17
US20220227813A1 (en) * 2019-05-14 2022-07-21 Ichimaru Pharcos Co., Ltd. Ras INHIBITORY PEPTIDE
TW202118770A (zh) 2019-07-30 2021-05-16 英商拜西可泰克斯有限公司 異質雙環肽複合物
WO2021198534A1 (en) 2020-04-04 2021-10-07 Oxurion NV Plasma kallikrein inhibitors for use in the treatment of coronaviral disease
WO2021229238A1 (en) * 2020-05-15 2021-11-18 Bicycletx Limited Anti-infective bicyclic peptide ligands
WO2023144030A1 (en) 2022-01-31 2023-08-03 Oxurion NV Plasma kallikrein inhibitor therapy for anti-vegf sensitization
WO2023148016A1 (en) 2022-02-04 2023-08-10 Oxurion NV Biomarker for plasma kallikrein inhibitor therapy response

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0205527D0 (en) * 2002-03-08 2002-04-24 Ferring Bv Inhibitors
EP1452868A2 (en) 2003-02-27 2004-09-01 Pepscan Systems B.V. Method for selecting a candidate drug compound
EP1844337B1 (en) 2005-01-24 2013-07-03 Pepscan Systems B.V. Binding compounds, immunogenic compounds and peptidomimetics
DK1854477T3 (en) 2006-03-16 2016-11-28 Dyax Corp Peptide inhibitors of plasma kallikrein for use in the treatment of eye disorders
DK2474613T3 (da) 2008-02-05 2014-10-06 Bicycle Therapeutics Ltd Fremgangsmåder og sammensætninger
GB0913775D0 (en) * 2009-08-06 2009-09-16 Medical Res Council Multispecific peptides
JP2013518807A (ja) * 2010-02-04 2013-05-23 メディカル リサーチ カウンシル 多重特異性ペプチド
LT3299377T (lt) * 2011-10-07 2021-03-25 Bicyclerd Limited Struktūrizuoto polipeptido specifiškumo moduliavimas
GB201117428D0 (en) * 2011-10-07 2011-11-23 Bicycle Therapeutics Ltd Structured polypeptides with sarcosine linkers
US20140274759A1 (en) 2013-03-15 2014-09-18 Bicycle Therapeutics Limited Modification of polypeptides
GB201306623D0 (en) * 2013-04-11 2013-05-29 Bicycle Therapeutics Ltd Modulation of structured polypeptide specificity
BR112016008996B1 (pt) * 2013-10-28 2023-01-24 Bicyclerd Limited Ligante peptídico específico para calicreína plasmática e composição farmacêutica

Also Published As

Publication number Publication date
US10894808B2 (en) 2021-01-19
JP2019112412A (ja) 2019-07-11
US20160222063A1 (en) 2016-08-04
ES2715379T3 (es) 2019-06-04
AU2014343503B2 (en) 2019-01-17
JP7170081B2 (ja) 2022-11-11
RU2674604C2 (ru) 2018-12-11
US20190233475A1 (en) 2019-08-01
AU2014343503A1 (en) 2016-05-12
CN105683211A (zh) 2016-06-15
US10294274B2 (en) 2019-05-21
CA2927554C (en) 2022-11-29
EP3062823A2 (en) 2016-09-07
AU2019201173A1 (en) 2019-03-07
AU2019201173B2 (en) 2019-11-21
JP2021098755A (ja) 2021-07-01
CA2927554A1 (en) 2015-05-07
WO2015063465A2 (en) 2015-05-07
SG11201602889TA (en) 2016-05-30
EP3062823B1 (en) 2018-12-12
RU2016120641A (ru) 2017-12-05
CN105683211B (zh) 2020-10-20
WO2015063465A3 (en) 2015-09-11
JP2017502921A (ja) 2017-01-26
RU2016120641A3 (pt) 2018-07-02
BR112016008996B1 (pt) 2023-01-24
NZ719510A (en) 2022-07-01

Similar Documents

Publication Publication Date Title
BR112016008996A2 (pt) Ligante peptídico específico para calicreína plasmática e composição farmacêutica
BR112017008575A2 (pt) ligantes de peptídeos bicíclicos específicos a mt1-mmp
ZA201805905B (en) Neuroactive steriods, compositions, and uses thereof
HK1247214B (zh) 一種pdl-1抗體、其藥物組合物及其用途
HK1257373A1 (zh) 雙功能蛋白質和包含其的藥物組合物
DK3258939T3 (da) Neuroaktive steroider, sammensætninger og anvendelser heraf
EP2889308A4 (en) SUPERFAMIL ALPHA O CONOTOXIN PEPTIDE, PHARMACEUTICAL COMPOSITION AND USE THEREOF
DK3368554T3 (da) Langtidsvirkende fgf21-fusionsproteiner og farmaceutisk sammensætning omfattende samme
BR112013017080A8 (pt) Anticorpo ou fragmento funcional do mesmo que se liga a forma ativa de calicreína do plasma humano, composiçao farmacêutica e método de detecçao de calicreína do plasma em um paciente
EA201792245A1 (ru) Биоконъюгаты и их применения
BR112014016744A2 (pt) polipeptídeo, composição farmacêutica e método para a produção de um ou mais polipeptídeos
BR112018071082A2 (pt) benzodiazepinas nasais e inaladas oralmente
EP3345929A4 (en) FUSION POLYPEPTIDE CONTAINED WITH ANTI-INFLAMMATORY POLYPEPTIDE AND FERRITINE MONOMER FRAGMENT AND PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF INFLAMMATORY DISEASES THEREFOR AS AN ACTIVE SUBSTANCE
DK2950822T3 (da) Farmaceutisk sammensætning til beskyttelse af sår, tilvejebringelse af hæmostase eller forebyggelse af adhæsion i mave-tarm-kanalen
EP3505530A4 (en) SYNTHESISED HEAT RESISTANT PEPTIDE OF SCORPIO VENOM AND USES THEREOF
BR112016007012A2 (pt) composição de estabilizante à luz, composição de resina, e, peça de veículo.
EP3328368A4 (en) COMPOUNDS AND PHARMACEUTICAL COMPOSITION ASSOCIATED WITH UBIQUITINATION-PROTEASOME SYSTEM
AU2018301804A1 (en) Molecular guide system peptides and uses thereof
BR112017006969A2 (pt) peptídeo derivado de hsp70, composição farmacêutica para o tratamento ou a prevenção de câncer usando o mesmo, indutor de imunidade e método de produção de célula apresentadora de antígeno
ZA201603723B (en) Ezrin-derived peptides and pharmaceutical compositions thereof
ES2526109R2 (es) Péptido y composición farmacéutica para el tratamiento del cáncer
IL266526A (en) Recombinant virus, preparations containing it and its uses
EP3416975A4 (en) NEW ALPHA-CONOTOXIN PEPTIDES
DK3429577T3 (da) N-lipoinaminosyre eller peptid, derivater og anvendelser deraf
SE542188C2 (en) Supports for membrane enhanced peptide synthesis

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 47/00 (2006.01), C07K 7/08 (2006.01)

B25D Requested change of name of applicant approved

Owner name: BICYCLERD LIMITED. (GB)

B25G Requested change of headquarter approved

Owner name: BICYCLERD LIMITED. (GB)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/10/2014, OBSERVADAS AS CONDICOES LEGAIS